馬用藥物和補充劑市場按產品類型、治療類別、分銷管道、給藥途徑、最終用戶、劑型和動物年齡層分類 - 全球預測 2025-2032

預計到 2032 年，馬用藥物和補充劑市場規模將成長至 15.6293 億美元，複合年成長率為 5.96%。

主要市場統計數據
基準年2024年	9.8349億美元
預計2025年	10.434億美元
預測年份：2032年	1,562,930,000美元
複合年成長率（%）	5.96%

馬療法簡明說明，重點在於臨床重點、監管環境和醫療保健環境中相關人員的期望

馬用藥物和補充劑領域需要重點關注，以平衡臨床需求、監管監督和商業性可行性。日益複雜的治療方法、多樣化的最終用戶和多樣化的劑型共同構成了一個以準確性、安全性和可靠供應為首要考慮的環境。獸醫和牧場主需要能夠為成年馬、幼馬和一歲馬帶來可預測結果的產品，而研究實驗室和醫院則優先考慮有實證依據的配方和強大的不利事件監測。

同時，研究機構和醫院優先考慮有實證依據的配方和強力的不利事件監測。無論產品類型如何，藥品仍然是急性疾病和特異性疾病治療的核心，而補充劑則擴大用於預防性護理、體能支持和長期肌肉骨骼健康。同時，分銷管道正從傳統的獸藥店擴展到線上藥局和綜合醫院管道，這為低溫運輸管理、認證和法規遵從性帶來了新的考量。從概念到臨床的轉變也涉及應對不斷發展的治療類別，例如抗感染藥感染疾病和抗發炎藥物，這些藥物的劑型和給藥途徑對臨床應用有重大影響。

這些動態的結合需要研發、生產、監管和商業團隊之間的策略合作。專注於臨床效用、安全性和分銷完整性，使相關人員能夠優先考慮能夠在馬匹醫療保健領域帶來可衡量價值的投資和介入措施。

技術創新、監管現代化和不斷發展的獸醫護理模式如何從根本上改變馬療法的產品開發和交付

多種力量的交會重塑了馬匹治療的格局，這些力量正在改變產品的開發、檢驗和交付方式。生技藥品和疫苗平台的進步使得更有針對性的預防方法成為可能，而抗菌藥物管理的必要性則推動配方師和開發團隊朝著更複雜的抗感染疾病策略和替代支持模式邁進。同時，數位健康工具和遠端醫療正在改變獸醫諮詢時間，實現遠端監控，並影響產品的配製方式和依從性追蹤。

供應鏈和生產實踐也在不斷發展。隨著企業尋求縮短前置作業時間並減少對單一原料藥)來源的依賴，契約製造和區域生產中心日益受到青睞。同時，電子商務和直銷管道迫使企業重新思考包裝、序列化和低溫運輸通訊協定，以維持產品完整性和監管可追溯性。與此轉變相輔相成的是，企業更加重視配方科學，外用凝膠、口服粉劑和注射劑等創新產品提高了生物有效性和使用者便利性。

這種轉型為差異化提案主張創造了機會，但也對跨職能協調提出了新的要求。將臨床證據產生與靈活的生產、數位化分銷和清晰的監管策略相結合的公司將更有能力將創新轉化為商業性和臨床影響力。

評估 2025 年實施的美國關稅對馬匹醫療保健價值鏈的多方面營運、臨床和策略影響

2025年美國關稅對涉及馬科動物藥品和補充劑的組織的戰略考量產生了重大且多方面的影響。進口活性成分和成品的成本結構受到直接影響，促使採購團隊重新評估其供應商組合，並加快尋找替代供應商的資格。在實踐中，這導致企業更加重視區域採購、庫存緩衝，在某些情況下，甚至將關鍵製造流程回流或近岸外包，以降低未來的關稅風險。

除了採購之外，為了最大程度地降低關稅的影響，企業重新平衡物流，分銷模式也改變了。這種重組增加了對具有跨境能力的委託製造和第三方物流供應商的需求，並提高了關稅分類、原產地證明和貿易合規專業知識在商業營運中的重要性。小型製造商和專業藥局感受到了不成比例的壓力，因為它們通常缺乏應對成本衝擊或協商批量採購折扣的靈活性。

在臨床方面，關稅環境加劇了與動物用藥品客戶的價格談判，並促使企業重新關注成本效益和治療差異化。因此，產品團隊優先投資於能夠提高製劑效率、延長保存期限並實現低成本給藥途徑的專案。從策略角度來看，關稅引發了全行業對供應鏈彈性、企業稅務規劃以及區域化製造地與全球最佳化但受政策影響的供應鏈之間的利弊的重新評估。

可操作的細分資訊揭示了產品類型、治療層級、分銷管道、給藥途徑、最終用戶、配方和年齡層如何影響臨床採用

當考慮產品類型、治療層級、分佈、給藥途徑、最終用戶、配方和年齡層時，會發現幾個清晰的模式。藥品和補充劑作為互補類別發揮作用，藥品優先用於急性和疾病特異性干預，而補充劑更常用於長期護理計劃中的預防和結締組織支持。在治療類別中，感染疾病和抗發炎藥物仍然是臨床實踐的核心支柱。當需要經驗性治療時，感染疾病著重於Aminoglycosides、大環內酯類、青黴素類、磺胺類藥物和四環黴素。抗發炎藥物平衡皮質類固醇策略和非類固醇抗發炎藥物方案，以控制疼痛和炎症，同時最大限度地降低系統性風險。

隨著獸醫和醫院擴大從線上藥局和綜合獸醫管道獲取藥物，分銷偏好正在發生變化，這減少了重複處方箋的摩擦，並實現了依從性追蹤。注射劑仍然是許多急性和住院治療的必需品，可根據劑量要求和耐受性選擇肌肉注射、靜脈注射和皮下注射等給藥方式。口服製劑，尤其是粉末、糖漿和片劑，是門診治療的首選，尤其是在馬駒偏好和劑量準確性至關重要的情況下。外用製劑，例如乳膏、乳劑和凝膠，旨在局部治療，以減少全身暴露並支持肌肉骨骼和皮膚疾病的恢復。

終端使用者細分顯示，馬場和獸醫診所是高價值治療產品的主要購買者，而研究機構和門診服務則日益成為新型生技藥品和疫苗的早期採用者。因此，製劑選擇必須兼顧現場從業人員的操作偏好和醫院藥局的穩定性要求。此外，成年馬通常需要以肌肉骨骼健康和循環系統支持為重點的慢性病管理方案，幼馬需要更溫和的口服藥物和謹慎注射的注射劑，而一歲馬則處於過渡期，通常同時使用預防性補充劑和標準藥物。整合這些細分市場，產品團隊能夠更好地將開發重點與使用者工作流程和臨床決策標準結合。

區域情報揭示美洲、歐洲、中東、非洲和亞太地區馬藥市場的需求促進因素、監管變化和商業化策略

區域動態塑造需求促進因素、監管預期和商業化策略，而這些因素往往被全球產品團隊低估。美洲擁有相對先進的臨床基礎設施，主要集中在大型獸醫院和專科馬科診所，有力地支持了實證醫學和優質補充劑的發展。該地區的臨床方案和付款人模式鼓勵對新型疫苗和生技藥品的投資，而成熟的分銷網路則支持診所直銷和線上藥房管道。

在歐洲、中東和非洲，監管的多樣性和農場結構的差異導致了商業性模式的複雜化。歐洲市場強調嚴格的藥物安全檢測和抗菌藥物管理，這會影響某些全身性藥物的標籤檢視、使用指南和可接受性。中東和非洲次區域由於進口物流、低溫運輸基礎設施和區域特定疾病壓力的差異，增加了額外的複雜性，所有這些都影響了產品優先順序和市場進入策略。

亞太地區正經歷著都市區獸醫診所的快速應用以及新興馬術休閒和運動領域需求的成長。雖然該地區的製造能力和原料採購有利於供應的連續性，但不同市場的法律規範和進口慣例差異很大。貿易政策和關稅動態持續影響著各地區的採購決策，而那些制定以區域為重點的監管備案、經銷夥伴和定價策略的公司將佔據有利地位，能夠抓住任何需求。

專注於創新、製造策略和夥伴關係模式的競爭與合作觀點塑造了馬療法領域的領導力

馬科動物治療領域的競爭格局以大型動物用藥品公司、專業動物用藥品公司、生物技術公司和複合藥房為特徵。老字型大小企業利用其廣泛的製造地、多樣化的產品組合和全球分銷協議來推動臨床滲透。這些公司往往優先考慮實證醫學證據豐富的產品，例如疫苗、循環系統藥物和關鍵抗感染藥感染疾病，同時也投資於生命週期管理和配方改進，以維持臨床偏好。

參與企業和生物技術參與企業正透過有針對性的創新來脫穎而出，例如下一代生技藥品、改進的止痛方式以及提高生物有效性並減少給藥頻率的配方科學。這些公司經常與研究機構和獸醫診所建立策略聯盟，以加速臨床檢驗並獲得早期採用者群體。受託製造廠商和第三方物流供應商正成為競爭定位的核心，能夠在限制資本支出的同時，實現更快的市場進入和靈活的規模擴張。

總體而言，成功的策略將包括整合的商業模式，該模式將清晰地描述臨床價值、嚴格的監管申報、與獸醫的直接互動、數位教育平台以及高效的分銷相結合。能夠展示可重複的臨床結果、確保供應鏈彈性並為最終用戶提供有效支援服務的公司通常將獲得更強大的市場吸引力，並建立更持久的客戶關係。

為領導者提供實用且優先的建議，以加強供應彈性、擴大臨床證據並最佳化馬匹護理的商業化。

產業領導者應協同採取一系列行動，以增強韌性，加速臨床應用，並改善商業性成果。首先，透過多元化供應網路和加快替代原料藥和最終產品來源的認證，減輕政策衝擊和關稅導致的成本波動的影響。同時，優先投資於製劑科學，以降低給藥複雜性，提高在不同物流條件下的穩定性，並解決特定年齡層的耐受性，從而提高農民和門診病人在現實世界中的依從性。

第二，我們將透過有針對性的臨床證據產生和以從業人員為中心的教育項目，深化與獸醫相關人員的合作。我們將產生可操作的臨床數據，突顯成本效益、安全性和易用性，從而支持醫院、診所和農場管理者採用此技術。第三，我們將結合診所直銷模式和高效的線上藥局管道，最佳化分銷，確保產品序列化和可追溯性，以維護產品完整性並打擊假冒仿冒品。

第四，制定監管和貿易合規策略，以因應關稅變化和不同的區域要求。透過提升關稅分類、原產國文件和監管協調方面的能力，加快市場進入並縮短上市時間。最後，探索與契約製造製造商、研究機構和技術提供者的合作，以共用擔風險、加速創新並配套服務，從而提升從業者的價值提案。這些合作措施將有助於永續成長，同時管理短期營運風險。

我們的研究結果以透明的混合方法研究途徑為基礎，該方法結合了相關人員訪談、文獻綜述、細分框架和檢驗通訊協定。

本文呈現的研究結果源自於混合方法研究途徑，旨在平衡主要利害關係人的見解和嚴謹的二手證據。主要資料收集包括對執業相關人員、醫院管理人員、馬場採購人員、配方科學家和高級公司高管的結構化訪談，提供有關臨床決策促進因素和營運限制的一線觀點。這些定性資訊還輔以同行評審的臨床文獻、監管指南、專利申請和公開的臨床試驗註冊庫，以確保技術準確性並揭示新興創新。

所採用的分析架構包括跨產品類型、治療類別、分銷管道、給藥途徑、最終用戶、劑型和年齡層的細分分析，以及用於評估干預措施和供應鏈突發事件的情境規劃。為了檢驗研究結果，我們採用了多階段的三角測量法，將訪談證據與第二手資料和跨區域貿易資料結合。專家小組審查提供了進一步的檢驗，重點關注臨床和商業性相關性。研究的局限性包括數據可用性的地區差異以及干涉措施的不斷發展變化，這些變化可能會改變競爭格局。在適當的情況下，方法附錄中提供了假設和置信水平，以幫助解釋。

總結性綜合報告重點強調了馬匹治療生態系統相關人員的策略重點、新興風險和機會途徑

最後，馬科動物藥品和補充劑行業的相關人員必須應對雙重挑戰：一方面要提供臨床上可靠且方便用戶使用的治療方法，另一方面要管理日益複雜的政策和供應鏈環境。治療重點、不斷發展的分銷管道以及區域監管差異之間的相互作用，需要靈活的籌資策略、清晰的臨床證據和靈活的商業模式。 2025年推出的關稅趨勢凸顯了供應鏈多元化和主動貿易合規的必要性，這將促使策略轉變，這將在可預見的未來影響採購和製造決策。

同樣重要的是，產品開發應與實際獸醫工作流程和年齡層給藥保持一致，以確保配方符合馬場、門診、研究實驗室和醫院的實際需求。將嚴格的臨床檢驗與靈活的生產安排和地理策略結合的組織，將最有可能獲得持續的價值。最終，最成功的公司將是那些將創新與明確的從業者利益相結合，同時保持營運韌性以應對外部衝擊的公司。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• 快速採用標靶單株抗體療法治療馬蹄葉炎
• 結合益生元和益生菌的合合益素元配方對馬腸道健康的需求日益成長
• 植物來源黃酮類化合物在治療馬關節炎和運動功能的應用日益增多
• 擴展的馬營養基因組檢測服務允許客製化營養補充方案
• 嚴格的歐盟法規推動馬療法核准和合規途徑的創新
• 增加注射長效止痛藥的使用以改善馬術後疼痛管理
• 開發水溶性維生素複合物以維持比賽馬的電解質平衡
• 整合人工智慧驅動的性能遙測技術，以最佳化馬匹補充計畫和劑量
• 專注於永續來源的海洋膠原蛋白和Omega-3酸，用於馬皮和關節營養

第6章 2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 馬用藥品和補品市場（依產品類型）

• 製藥
• 補充

9. 馬用藥物和補充劑市場（按治療類別）

• 麻醉劑
• 抗感染藥物
  • Aminoglycosides
  • 大環內酯類
  • 青黴素
  • 磺胺類藥物
  • 四環黴素
• 抗發炎藥物
  • 皮質類固醇
  • NSAIDs
• 心血管藥物
• 胃腸藥
• 荷爾蒙製劑
• 神經系統藥物
• 疫苗

第 10 章。馬藥和補品市場（按分銷管道）

• 網路藥局
• 零售藥局
• 獸醫診所
• 獸醫藥房

第 11 章。按給藥途徑分類的馬用藥物和補充劑市場

• 注射
  • 肌肉注射
  • 靜脈
  • 皮下
• 口服
  • 粉末
  • 糖漿
  • 藥片
• 局部的

第 12 章：馬用藥品和補品市場（依最終用戶分類）

• 馬場
• 研究和學術機構
• 獸醫診所和門診服務
• 獸醫診所

第 13 章：馬用藥品和補充劑市場（按劑型）

• 奶油
• 乳劑
• 凝膠
• 粉末
• 解決方案
• 藥片

第 14 章。馬用藥品和補品市場（以動物年齡層）

• 成年馬
• 駒
• 一歲鴿

第15章 馬用藥品和補品市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第 16 章：馬用藥品和補品市場（依類別）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第 17 章：按國家分類的馬藥和補品市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第18章競爭格局

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim Animal Health GmbH
  • Elanco Animal Health Incorporated
  • Ceva Sante Animale SAS
  • Dechra Pharmaceuticals plc
  • Virbac SA
  • Vetoquinol SA
  • Phibro Animal Health Corporation
  • Neogen Corporation

The Equine Pharmaceuticals & Supplements Market is projected to grow by USD 1,562.93 million at a CAGR of 5.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 983.49 million
Estimated Year [2025]	USD 1,043.40 million
Forecast Year [2032]	USD 1,562.93 million
CAGR (%)	5.96%

A concise orientation to the equine therapeutics landscape highlighting clinical priorities, regulatory responsibilities, and stakeholder expectations across care settings

The equine pharmaceuticals and supplements domain demands a focused orientation that balances clinical need, regulatory oversight, and commercial practicality. Increasingly complex therapeutic regimens, diversified end users, and a broader array of delivery formats have combined to create a landscape where precision, safety, and supply reliability are paramount. Veterinarians and farm managers require products that deliver predictable outcomes across adult horses, foals, and yearlings, while research institutions and hospitals prioritize evidence-backed formulations and robust adverse event monitoring.

Across product distinctions, pharmaceuticals continue to anchor acute care and disease-specific treatments, while supplements are often deployed for preventive care, performance support, and long-term musculoskeletal health. Meanwhile, distribution has broadened beyond traditional veterinary pharmacies to include online pharmacies and integrated hospital channels, introducing new considerations around cold-chain management, authentication, and regulatory compliance. Transitioning from concept to clinic also involves navigating evolving therapeutic categories such as anti-infectives and anti-inflammatories, where formulation and route of administration materially impact clinical adoption.

Taken together, these dynamics require strategic alignment across R&D, manufacturing, regulatory affairs, and commercial teams. By foregrounding clinical utility, safety, and distribution integrity, stakeholders can better prioritize investments and interventions that deliver measurable value in equine care settings.

How technological innovation, regulatory modernization, and evolving veterinary care models are fundamentally altering product development and delivery in equine therapeutics

The equine therapeutics landscape is being reshaped by multiple intersecting forces that are altering how products are developed, validated, and delivered. Advances in biologics and vaccine platforms are enabling more targeted preventive approaches, even as antimicrobial stewardship imperatives push formulators and prescribers toward refined anti-infective strategies and alternative supportive modalities. Concurrently, digital health tools and telemedicine are changing the cadence of veterinary consultations and enabling remote monitoring, which affects how products are prescribed and how adherence is tracked.

Supply chain and manufacturing practices are also evolving. Contract manufacturing and regional production hubs are gaining traction as companies seek to shorten lead times and reduce reliance on single-source active pharmaceutical ingredient suppliers. At the same time, e-commerce and direct-to-practice distribution channels are forcing companies to rethink packaging, serialization, and cold-chain protocols to maintain product integrity and regulatory traceability. These shifts are complemented by a heightened focus on formulation science, where innovations in topical gels, oral powders, and injectable presentations are improving bioavailability and user convenience.

Together, these transformations create opportunities for differentiated value propositions, but they also impose new requirements for cross-functional coordination. Firms that align clinical evidence generation with flexible manufacturing, digital-enabled distribution, and clear regulatory strategies will be better positioned to translate innovation into commercial and clinical impact.

Assessing the multifaceted operational, clinical, and strategic consequences of the United States tariff measures introduced in 2025 on the equine therapeutics value chain

The 2025 tariff measures introduced by the United States have had a material and multifaceted influence on the operational and strategic calculus of organizations involved in equine pharmaceuticals and supplements. Cost structures for imported active ingredients and finished goods were directly affected, prompting procurement teams to reassess supplier portfolios and to accelerate qualification of alternative sources. In practice, this has meant a stronger emphasis on regional sourcing, inventory buffering, and in some cases, reshoring or nearshoring of critical manufacturing steps to mitigate future policy risk.

Beyond procurement, distribution patterns shifted as companies rebalanced logistics to minimize tariff exposure. This rebalancing increased demand for contract manufacturers and third-party logistics providers with cross-border capabilities, and it elevated the importance of tariff classification, origin documentation, and trade compliance expertise within commercial operations. Smaller manufacturers and specialized compounding pharmacies felt disproportionate pressure, as they typically have less flexibility to absorb cost shocks or negotiate bulk purchase discounts.

Clinically, the tariff environment translated into tighter price negotiations with veterinary customers and a renewed focus on demonstrating cost-effectiveness and therapeutic differentiation. As a result, product teams prioritized investments that enhanced formulation efficiency, extended shelf life, or enabled lower-cost routes of administration. From a strategic perspective, the tariffs catalyzed a broader industry reassessment of supply chain resilience, corporate tax planning, and the merits of localized manufacturing footprints versus a globally optimized but policy-exposed supply chain.

Actionable segmentation intelligence revealing how product types, therapeutic classes, distribution channels, administration routes, end users, formulations, and age groups inform clinical adoption

Segmentation offers the most direct route to actionable differentiation in equine therapeutics, and several clear patterns emerge when product type, therapeutic class, distribution, route of administration, end user, formulation, and animal age group are considered together. Pharmaceuticals and supplements function as complementary categories; pharmaceuticals are prioritized for acute and disease-specific interventions, while supplements are more commonly adopted for preventive and connective tissue support across long-term care plans. Within therapeutic categories, anti-infectives and anti-inflammatories remain core pillars of clinical practice, with anti-infectives emphasizing agents such as aminoglycosides, macrolides, penicillins, sulfonamides, and tetracyclines when empirical coverage is needed, and anti-inflammatories balancing corticosteroid strategies against NSAID regimens to manage pain and inflammation while minimizing systemic risk.

Distribution preferences are shifting as veterinarians and hospitals increasingly source through online pharmacies and integrated veterinary hospital channels, reducing friction for repeat prescriptions and enabling better adherence tracking. Injectable presentations continue to be essential for many acute and inpatient interventions, with intramuscular, intravenous, and subcutaneous options selected based on onset requirements and tolerability. Oral forms, particularly powders, syrups, and tablets, are favored for outpatient management and for foals where palatability and dosing precision are critical. Topical formulations, including creams, emulsions, and gels, offer targeted local therapy that reduces systemic exposure and supports recovery in musculoskeletal and dermatological conditions.

End-user segmentation reveals that equine farms and veterinary hospitals are primary purchasers of high-value therapeutic products, whereas research institutions and ambulatory services increasingly influence early adoption of novel biologics and vaccines. Formulation choices must therefore reconcile handling preferences of field practitioners with the stability demands of hospital pharmacies. Moreover, age-group considerations are integral to product positioning: adult horses often require chronic management solutions focused on musculoskeletal health and cardiovascular support, foals demand gentler oral and injectables with careful dosing, and yearlings fall into a transitional category where both preventive supplements and standard pharmaceuticals are commonly used. By integrating these segmentation dimensions, product teams can better align development priorities with user workflows and clinical decision-making criteria.

Regional intelligence unpacking demand drivers, regulatory variation, and commercialization strategies across the Americas, EMEA, and Asia-Pacific equine care markets

Regional dynamics shape demand drivers, regulatory expectations, and commercialization strategies in ways that are often underappreciated by global product teams. In the Americas, clinical infrastructures are relatively advanced and concentrated in high-volume veterinary hospitals and specialist equine clinics, yielding strong uptake of evidence-backed pharmaceuticals and premium supplements. Clinical protocols and payer models in this region encourage investment in novel vaccines and biologics, and the presence of well-established distribution networks supports both direct-to-practice and online pharmacy channels.

In Europe, Middle East and Africa, regulatory heterogeneity and differing farm structures create a mosaic of commercial approaches. European markets emphasize stringent pharmacovigilance and antimicrobial stewardship, which affects labeling, usage guidance, and the acceptability of certain systemic agents. Middle Eastern and African subregions introduce additional complexity with variations in import logistics, cold-chain infrastructure, and localized disease pressure, all of which influence product prioritization and go-to-market tactics.

Asia-Pacific presents a distinct mix of rapid adoption in urban veterinary centers and growing demand from emerging equine leisure and sport segments. Manufacturing capacity and ingredient sourcing in the region can be advantageous for supply continuity, yet regulatory frameworks and import practices vary considerably from market to market. Across all regions, trade policies and tariff dynamics continue to exert influence on sourcing decisions, and companies that craft region-specific regulatory filings, distribution partnerships, and pricing strategies will be better positioned to capture the full spectrum of demand.

Competitive and collaborative company-level perspectives emphasizing innovation focus, manufacturing strategy, and partnership models shaping equine therapeutics leadership

Competitive landscapes in equine therapeutics are characterized by a mixture of large animal health companies, specialized veterinary pharmaceutical firms, biotech innovators, and compounding pharmacies. Established firms often leverage broad manufacturing footprints, diversified portfolios, and global distribution agreements to support widespread clinical penetration. They tend to prioritize high-evidence products such as vaccines, cardiovascular agents, and key anti-infectives, while also investing in lifecycle management and formulation improvements to retain clinical preference.

Specialist players and biotech entrants are differentiating through targeted innovation, such as next-generation biologics, improved analgesic modalities, and formulation science that enhances bioavailability or reduces administration frequency. These firms frequently pursue strategic partnerships with research institutions and veterinary hospitals to accelerate clinical validation and to access early-adopter cohorts. Contract manufacturing organizations and third-party logistics providers are increasingly central to competitive positioning, enabling faster market entry and flexible scaling while allowing companies to control capital expenditure.

Across the competitive set, successful strategies include clear articulation of clinical value, robust regulatory dossiers, and integrated commercial models that combine direct engagement with veterinarians, digital education platforms, and efficient distribution. Firms that can demonstrate reproducible clinical outcomes, secure supply chain resilience, and offer effective support services for end users will generally achieve stronger market traction and more durable customer relationships.

Practical and prioritized recommendations for leaders to reinforce supply resilience, amplify clinical evidence, and optimize commercialization in equine therapies

Industry leaders should pursue a coordinated set of actions that enhance resilience, accelerate clinical adoption, and improve commercial outcomes. First, diversify supplier networks and accelerate qualification of alternative API and finished-goods sources to reduce exposure to policy shocks and tariff-driven cost volatility. Concurrently, prioritize investments in formulation science that lower administration complexity, improve stability under varied logistics conditions, and address specific age-group tolerability, thereby increasing real-world adherence among farm-based and ambulatory users.

Second, deepen engagement with veterinary stakeholders through targeted clinical evidence generation and practitioner-focused education programs. Generating pragmatic clinical data that highlights cost-effectiveness, safety, and ease of administration will support uptake among hospitals, clinics, and farm managers. Third, optimize distribution by combining direct-to-practice models with validated online pharmacy channels, ensuring serialization and traceability to preserve product integrity and combat counterfeiting.

Fourth, prepare regulatory and trade-compliance strategies that anticipate tariff shifts and heterogeneous regional requirements. Building capabilities in tariff classification, origin documentation, and regulatory harmonization will accelerate market access and reduce time-to-shelf. Finally, explore collaborative ventures with contract manufacturers, research institutions, and technology providers to share risk, accelerate innovation, and create bundled service offerings that enhance practitioner value propositions. These coordinated measures will support sustainable growth while managing near-term operational exposure.

Transparent mixed-methods research approach combining stakeholder interviews, literature review, segmentation frameworks, and validation protocols to underpin findings

The findings presented here are derived from a mixed-methods research approach designed to balance primary stakeholder insight with rigorous secondary evidence. Primary data collection included structured interviews with practicing veterinarians, hospital administrators, procurement leads at equine farms, formulation scientists, and senior commercial executives, providing frontline perspectives on clinical decision drivers and operational constraints. These qualitative inputs were complemented by a review of peer-reviewed clinical literature, regulatory guidance, patent filings, and publicly available clinical trial registries to ensure technical accuracy and to contextualize emergent innovations.

Analytical frameworks employed include segmentation analysis across product type, therapeutic category, distribution channel, route of administration, end user, formulation, and age group, as well as scenario planning to evaluate policy and supply chain contingencies. Triangulation was used at multiple stages to validate insights, combining interview evidence with secondary documentation and cross-regional trade data. An expert panel review provided an additional layer of validation, focusing on clinical plausibility and commercial relevance. Limitations include regional variation in data availability and the evolving nature of policy interventions that may change the competitive environment; where appropriate, assumptions and confidence levels are documented in the methodology annex to aid interpretation.

Concluding synthesis crystallizing strategic priorities, emergent risks, and opportunity pathways for stakeholders across the equine therapeutics ecosystem

In closing, stakeholders operating in the equine pharmaceuticals and supplements sector must reconcile a dual imperative: deliver clinically robust, user-friendly therapies while managing an increasingly complex policy and supply chain environment. The interplay of therapeutic priorities, distribution channel evolution, and regional regulatory variation requires nimble sourcing strategies, clear clinical evidence, and adaptive commercial models. Tariff dynamics introduced in 2025 have underscored the necessity of supply chain diversification and proactive trade compliance, catalyzing strategic shifts that will influence sourcing and manufacturing decisions for the foreseeable future.

Equally important is the need to align product development with real-world veterinary workflows and age-specific dosing considerations, ensuring that formulations meet the practical demands of equine farms, ambulatory services, research institutions, and hospitals. Organizations that integrate rigorous clinical validation with flexible manufacturing arrangements and targeted regional strategies will be best placed to capture sustained value. Ultimately, the most successful participants will be those that translate technical innovation into clear practitioner benefits while maintaining operational resilience against external shocks.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid adoption of monoclonal antibody therapies targeting equine laminitis management
• 5.2. Growing demand for synbiotic formulations combining prebiotics and probiotics for equine gut health
• 5.3. Surge in plant-based flavonoid compounds for equine joint inflammation and mobility support
• 5.4. Introduction of digital dosing devices integrating IoT sensors in equine pharmaceutical administration
• 5.5. Expansion of equine nutrigenomic testing services to customize dietary supplement regimens
• 5.6. Stringent EU regulations driving innovation in equine therapeutic approval and compliance pathways
• 5.7. Rising utilization of injectable long-acting analgesics to improve equine postoperative pain control
• 5.8. Development of water-soluble vitamin complexes to address electrolyte imbalance in sport horses
• 5.9. Integration of AI-driven performance telemetry to optimize equine supplement schedules and dosages
• 5.10. Focus on sustainably sourced marine collagen and omega-3 acids for equine coat and joint nutrition

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Equine Pharmaceuticals & Supplements Market, by Product Type

• 8.1. Pharmaceuticals
• 8.2. Supplements

9. Equine Pharmaceuticals & Supplements Market, by Therapeutic Category

• 9.1. Anesthetic Agents
• 9.2. Anti-Infectives
  • 9.2.1. Aminoglycosides
  • 9.2.2. Macrolides
  • 9.2.3. Penicillins
  • 9.2.4. Sulfonamides
  • 9.2.5. Tetracyclines
• 9.3. Anti-Inflammatories
  • 9.3.1. Corticosteroids
  • 9.3.2. NSAIDs
• 9.4. Cardiovascular Agents
• 9.5. Gastrointestinal Agents
• 9.6. Hormonal Preparations
• 9.7. Nervous System Agents
• 9.8. Vaccines

10. Equine Pharmaceuticals & Supplements Market, by Distribution Channel

• 10.1. Online Pharmacies
• 10.2. Retail Pharmacies
• 10.3. Veterinary Hospitals & Clinics
• 10.4. Veterinary Pharmacies

11. Equine Pharmaceuticals & Supplements Market, by Route Of Administration

• 11.1. Injectable
  • 11.1.1. Intramuscular
  • 11.1.2. Intravenous
  • 11.1.3. Subcutaneous
• 11.2. Oral
  • 11.2.1. Powders
  • 11.2.2. Syrups
  • 11.2.3. Tablets
• 11.3. Topical

12. Equine Pharmaceuticals & Supplements Market, by End User

• 12.1. Equine Farms
• 12.2. Research Institutions & Academics
• 12.3. Veterinary Clinics & Ambulatory Services
• 12.4. Veterinary Hospitals

13. Equine Pharmaceuticals & Supplements Market, by Formulation

• 13.1. Creams
• 13.2. Emulsions
• 13.3. Gels
• 13.4. Powders
• 13.5. Solutions
• 13.6. Tablets

14. Equine Pharmaceuticals & Supplements Market, by Animal Age Group

• 14.1. Adult Horses
• 14.2. Foals
• 14.3. Yearlings

15. Equine Pharmaceuticals & Supplements Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Equine Pharmaceuticals & Supplements Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Equine Pharmaceuticals & Supplements Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. Zoetis Inc.
  • 18.3.2. Merck & Co., Inc.
  • 18.3.3. Boehringer Ingelheim Animal Health GmbH
  • 18.3.4. Elanco Animal Health Incorporated
  • 18.3.5. Ceva Sante Animale SAS
  • 18.3.6. Dechra Pharmaceuticals plc
  • 18.3.7. Virbac SA
  • 18.3.8. Vetoquinol SA
  • 18.3.9. Phibro Animal Health Corporation
  • 18.3.10. Neogen Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FOALS, BY REGION, 20